Alzamend Neuro, Inc. Common Stock (ALZN) Stock Price
ALZNStock
$1.66−31.69%52W
Market Cap$8.01M
P/E—
PEG Ratio—
Div yield—
Beta0.34
ALZN Share Price Chart
Favorite Metrics
Price vs S&P 500 (26W)-32.50%
Price vs S&P 500 (4W)22.34%
VGM Score61.84
ALZN Earnings Surprise History
| Quarter | Report date | EPS estimate | EPS actual | Surprise |
|---|---|---|---|---|
| Q1 2026 | -$0.67 | -$0.74 | -10.45%(-$0.07) | |
| Q4 2025 | -$0.53 | -$0.58 | -9.43%(-$0.05) | |
| Q3 2025 | -$1.96 | -$0.30 | +84.65%(+$1.66) | |
| Q2 2025 | -$0.69 | -$1.28 | -85.51%(-$0.59) | |
| Q1 2025 | -$2.70 | -$9.48 | -251.11%(-$6.78) |
ALZN Analyst Recommendations
May 2026
Jun 2026
Jul 2026
Aug 2026
4.00
4.14
4.14
4.14
Industry Peers — Pharmaceuticals(570)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
ALZNAlzamend Neuro, Inc. Common Stock | — | — | B | $1.66 |
| LLYEli Lilly & Co. | D | B | C | $1174.61 |
| JNJJohnson & Johnson | D | C | B | $268.04 |
| ABBVABBVIE INC. | D | C | B | $255.48 |
| MRKMerck & Co., Inc. | D | C | B | $148.35 |
| NVSNovartis AG | C | C | C | $153.81 |
| AZNAstraZeneca PLC | C | B | C | $162.70 |
| NVONovo-Nordisk A/S | B | C | C | $45.61 |
| ABTAbbott Laboratories | C | C | C | $112.47 |
| PFEPfizer Inc. | C | D | B | $27.96 |
| VRTXVertex Pharmaceuticals Inc | D | C | B | $541.69 |
About Alzamend Neuro, Inc. Common Stock
Alzamend Neuro is an early-stage biopharmaceutical company developing novel therapies for neurodegenerative diseases and psychiatric disorders, with a focus on Alzheimer's disease. Its pipeline consists of AL001, a patented lithium-based ionic cocrystal technology, and AL002, a cell-based therapeutic vaccine designed to restore immune response against Alzheimer's.